@FiercePharma: Top-read on FP Monday: Should deal-needy Pfizer target antibiotics specialist Cubist? Article | Follow @FiercePharma
@TracyStaton: ICYMI yesterday: @NovoNordisk CEO on the house that Victoza built and the future of diabetes R&D. Report | Follow @TracyStaton
@EricPFierce: Indian drugmaker, Marck Biosciences, ravaged by FDA warning letter for records kept on 'scratch paper.' Story | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Reckitt Benckiser chief ahead of the consumer health curve, analysts say. Article | Follow @CarlyHFierce
> Bristol-Myers Squibb ($BMY) is eyeing a big move into office and lab space in Cambridge, MA, targeting 200,000 square feet in the Kendall Square area, a hotbed of drug development. Report
> The U.S. Sixth Circuit kicked Novartis ($NVS) back to trial court in a case over jaw injuries allegedly linked to its bone drugs Aredia and Zometa. Report
> U.K. cost-effectiveness gatekeepers agreed to reconsider Ferring Pharmaceuticals' prostate cancer treatment Firmagon (degarelix), previously rejected for routine use by the National Health Service. Report
> Indian drugmakers are facing more frequent bars against launching generic versions of patented drugs, with more than 10 so far this year, up from a half dozen for all of 2012. Report
Medical Device News
@FierceMedDev: Blood test for drug-resistant malaria strain shows promise. FierceDiagnostics story | Follow @FierceMedDev
@StacyALawrence: ICYMI yesterday: Abbott gets $20M from DoD to develop portable concussion test. Article | Follow @StacyALawrence
@VarunSaxena2: My photo was published in @indystar! George Will: Progressives as economic innocents. Story via IndyStar | Follow @VarunSaxena2
@EmilyWFierce: Medtronic sticks to its guns on Covidien and reports strongest quarterly U.S. sales growth in 5 years. More from Reuters | Follow @EmilyWFierce
> Leading U.S. hospital group target of external cyberattack. News
> Feds looking to fund clinical studies on cardiology, hip fracture and surgical mesh, among other topics. More
> Cheap, portable Dx device detects an array of medical and environmental conditions. Article
Biotech News
@FierceBiotech: Amgen successfully hits another PhIII goal line with kidney dialysis drug. Story | Follow @FierceBiotech
@JohnCFierce: On again: Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal. Article | Follow @JohnCFierce
@DamianFierce: If Zosano Pharma $ZSAN pulls off its IPO this week, it'll be the 52nd biotech to go public this year, per @IPOtweet. | Follow @DamianFierce
@EmilyMFierce: Over-hyped headline, but excellent points here: You Are Not Nearly Scared Enough About Ebola. More | Follow @EmilyMFierce
> Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal. Story
> Lilly grabs a 'tentative' FDA OK for insulin treatment, but Sanofi still blocks its path. More
> Dermira pockets $51M to bankroll skin treatments. News
> Amgen successfully hits another PhIII goal line with kidney dialysis drug. Article
Biotech Research News
> Bacteria injection shrinks tumors in animals. Report
> Diabetes culprit may be a single enzyme. Story
> Researchers unveil lung-on-a-chip device. Article
> Ebola protein discovery could aid drug development. More
> Organovo 3-D printed liver tissue moves closer to market. Item
Pharma Manufacturing News
> FDA warning letter says Marck plant plagued by faked records and dead frogs. Report
> Sweden's Recipharm moves on Italy with $160M deal for Corvette. More
> Big Pharma stands back as little guys work on plant-based drugs and manufacturing. Report
> Sun Pharma recalls nearly 500,000 bottles of antibiotics. Story
> Sanofi shipping new malaria treatment manufactured from 'semisynthetic artemisinin.' Article
And Finally... Too many cancer screenings are given to elderly people likely to die within a decade, a study found. Report